Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I.

J Am Soc Nephrol. 2011 May;22(5):956-66. doi: 10.1681/ASN.2010080894. Epub 2011 Mar 24.

2.

Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.

Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, Valero R, Rafael S, Veganzones S, Calvo N, De la Orden V, De la Flor JC, Valga F, Vidaurreta M, Fernández-Pérez C, Barrientos A.

Nephrol Dial Transplant. 2012 Nov;27(11):4227-35. doi: 10.1093/ndt/gfs409.

PMID:
23144073
3.

Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation.

Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH; NIGRAM Consortium..

Clin J Am Soc Nephrol. 2013 Nov;8(11):1968-78. doi: 10.2215/CJN.01880213. Epub 2013 Aug 8.

4.

Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M; CRIC Study Investigators..

Nephrol Dial Transplant. 2015 Sep;30(9):1534-41. doi: 10.1093/ndt/gfv123. Epub 2015 Apr 24.

5.

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.

Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9. Erratum in: Kidney Int. 2012 Aug;82(4):498.

6.

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1989-1998. Epub 2016 Aug 25.

PMID:
27561289
7.

Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.

Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.

Transplant Proc. 2012 Nov;44(9):2551-4. doi: 10.1016/j.transproceed.2012.09.070.

PMID:
23146451
8.

Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.

Tomida K, Hamano T, Ichimaru N, Fujii N, Matsui I, Nonomura N, Tsubakihara Y, Rakugi H, Takahara S, Isaka Y.

Bone. 2012 Oct;51(4):729-36. doi: 10.1016/j.bone.2012.06.027. Epub 2012 Jul 14.

PMID:
22796419
9.

Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?

Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB.

Nephrol Dial Transplant. 2011 Nov;26(11):3779-84. doi: 10.1093/ndt/gfr126. Epub 2011 Mar 25.

10.

Renal phosphate loss in long-term kidney transplantation.

Sirilak S, Chatsrisak K, Ingsathit A, Kantachuvesiri S, Sumethkul V, Stitchantrakul W, Radinahamed P, Disthabanchong S.

Clin J Am Soc Nephrol. 2012 Feb;7(2):323-31. doi: 10.2215/CJN.06380611. Epub 2011 Dec 1.

11.

Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.

Marsell R, Grundberg E, Krajisnik T, Mallmin H, Karlsson M, Mellström D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE.

Eur J Endocrinol. 2008 Jan;158(1):125-9. doi: 10.1530/EJE-07-0534.

12.

The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.

Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.

Kidney Int. 2014 Aug;86(2):407-13. doi: 10.1038/ki.2013.537. Epub 2014 Jan 15.

PMID:
24429404
13.

Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H.

Atherosclerosis. 2014 Nov;237(1):53-9. doi: 10.1016/j.atherosclerosis.2014.08.037. Epub 2014 Aug 28.

PMID:
25200615
14.

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4.

PMID:
23129826
15.

Abnormalities in renal tubular phosphate handling in children with sickle cell disease.

Raj VM, Freundlich M, Hamideh D, Alvarez O, Seeherunvong W, Abitbol C, Katsoufis C, Chandar J, Ruiz P, Zilleruelo G.

Pediatr Blood Cancer. 2014 Dec;61(12):2267-70. doi: 10.1002/pbc.25188. Epub 2014 Aug 17.

PMID:
25132581
16.

Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.

Clin J Am Soc Nephrol. 2012 May;7(5):810-9. doi: 10.2215/CJN.08680811. Epub 2012 Feb 23.

17.

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group..

JAMA. 2011 Jun 15;305(23):2432-9. doi: 10.1001/jama.2011.826.

18.

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.

Bech AP, Bouma-de Krijger A, van Zuilen AD, Bots ML, van den Brand JA, Blankestijn PJ, Wetzels JF, Vervloet MG.

J Nephrol. 2015 Aug;28(4):477-84. doi: 10.1007/s40620-015-0178-0. Epub 2015 Feb 21.

19.

Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease.

Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, Chen J, Feldman H, Gutierrez OM, Lash J, Leonard MB, Negrea L, Rosas SE, Anderson AH, Townsend RR, Wolf M, Isakova T; Chronic Renal Insufficiency Cohort Study Group..

Diabetes Care. 2012 May;35(5):994-1001. doi: 10.2337/dc11-2235. Epub 2012 Mar 23.

20.

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y.

Bone. 2012 Jun;50(6):1266-74. doi: 10.1016/j.bone.2012.02.634. Epub 2012 Mar 6.

PMID:
22425694

Supplemental Content

Support Center